MoonLake Immunotherapeutics
MLTX
$16.47
-$0.03-0.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -61.81M | -69.71M | -62.43M | -69.73M | -55.22M |
| Total Depreciation and Amortization | 896.00K | 845.00K | 751.00K | 745.00K | 742.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.57M | 13.79M | 2.88M | 3.01M | 1.14M |
| Change in Net Operating Assets | 2.78M | -11.21M | 6.00K | 21.43M | -1.19M |
| Cash from Operations | -55.56M | -66.29M | -58.79M | -44.54M | -54.53M |
| Capital Expenditure | -- | -- | 0.00 | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 322.00K | 98.00K | -29.91M | 88.40M | 88.25M |
| Cash from Investing | 322.00K | 98.00K | -29.91M | 88.40M | 88.25M |
| Total Debt Issued | 0.00 | 24.47M | 0.00 | 0.00 | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 234.62M | 6.18M | 72.40M | 480.00K | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 234.62M | 30.64M | 72.40M | 480.00K | 0.00 |
| Foreign Exchange rate Adjustments | 29.00K | -483.00K | 91.00K | -285.00K | 1.39M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 179.42M | -36.03M | -16.22M | 44.06M | 35.12M |